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Abstract: Introduction: The inherent immunosuppression of uremia increases the susceptibility of
hemodialysis patients to infection. There is still limited evidence on hemodialysis patients and COVID-19.
The clinical and analytical spectrum and treatment responses and mortality are poorly characterized.
Material and Methods: Clinical and analytical features, chest X-ray, polymerase chain reaction (PCR)
and antibodies for SARS-CoV-2, treatment and outcomes were analyzed in 48 patients diagnosed with
COVID-19 during March and April 2020 in two coordinated Spanish hemodialysis units. Results:
In 200 haemodialysis patients, COVID-19 was diagnosed in 48, of whom 22 were PCR positive, eight PCR
negative but seroconverted and two were diagnosed on typical clinical grounds. Despite a mean age of
72.6 years, the overall mortality rate was 5/48 (10%). Among the PCR positive patients, 21 (55%) required
admission and five (13%) died. PCR positive patients were more often symptomatic and hospitalized
and had higher troponin I levels than PCR negative patients, but did not differ in lymphocyte counts,
D-dimer or interleukin-6 (IL-6) levels. Among PCR negative COVID-19 patients, three out of 10 (30%)
required admission, and none died. The most frequent symptom among the 48 patients was fever
(31%), followed by asymptomatic patients (23%). A low number of lymphocytes was the only parameter
significantly different between hospitalized and ambulatory COVID-19 patients, independently of PCR
status. Conclusions: COVID-19 hemodialysis patients are frequently asymptomatic, and mortality may be
lower than previously reported. Diagnosis may be retrospective, based on seroconversion, as PCR may be
negative. This information should guide preventive and patient isolation strategies.
Keywords: COVID-19; hemodialysis; chronic kidney disease; antibodies; asymptomatic; mortality
1. Introduction
In February 2020, the SARS-CoV-2 coronavirus epidemic that began in late December in Wuhan,
China, reached Madrid. Hemodialysis patients have higher mortality from any cause than the general
population. The leading cause of death is cardiovascular, followed by infections [1,2]. Lung infections
are the most common cause of infectious death [3] and sepsis mortality is 50 times higher than
in the general population [4]. Altered innate and adaptive immunity in uremia increases the risk
and severity of infections [5]. The increased sensitivity to infection coexists with a state of systemic
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inflammation [6,7]. Infections and death from cardiovascular causes are interrelated, so that the risk of
death from cardiovascular causes increases markedly after respiratory infections, in both the general
population and dialysis patients [8,9]. Specifically, mortality from viral causes is high in hemodialysis,
as the seasonal influenza virus can be complicated by pneumonia, bronchitis and myocarditis, among
others [10]. As the influenza virus is highly contagious, annual vaccination is recommended, despite
the suboptimal immune response of dialysis patients [11]. Six months after vaccination, only one-third
of hemodialysis patients maintain immunity [12]. These features of dialysis patients suggest that
coronavirus disease 2019 (COVID-19) may be more severe in hemodialysis patients. COVID-19 is
a highly contagious, slow course and potentially lethal disease that is more severe in patients with
comorbidities such as diabetes, cardiovascular disease and chronic kidney disease [13].
COVID-19 is characterized by high virus shedding from the upper respiratory tract even among
asymptomatic patients, which differentiates it from influenza [14–16]. Symptom-based detection alone
could not detect a high proportion of infectious individuals, failing to control transmission in closed
communities. Thus, it was recently recommended to perform routine polymerase chain reaction
(PCR) on contacts and newcomers, in addition to the symptomatic detection of new residents and the
periodic reassessment of the study population and staff, following a strategy similar to that successfully
containing the epidemic in South Korea, Singapore and Germany.
Information on the clinical course of COVID-19 in hemodialysis patients is scarce. In one
hemodialysis unit in China, there were 37 (16%) cases of COVID-19 among 230 patients and seven
out of 37 (19%) COVID-19 patients died [17]. In addition to lung lesions identified on a computed
tomography (CT) scan, the disease was accompanied by leukopenia and increased inflammatory
cytokines. This study alerted us to the high susceptibility of hemodialysis patients to and the high
mortality of COVID-19.
We now present the experience in a Spanish Dialysis Unit, collected two months after the first
COVID-19 case, and analyze the clinical and analytical characteristics, the immune response to the
virus, treatment and outcomes.
2. Materials and Methods
This was a retrospective observational study of COVID-19 in chronic hemodialysis patients
from two coordinated dialysis units: the Hemodialysis Unit of the Fundación Jiménez Diaz Hospital
(UHFJD), Madrid, Spain, and its associated center Fundación Renal Centro Santa Engracia (FRCSE).
UHFJD is a hospital-based hemodialysis unit that generally cares for patients with more comorbidity,
while FRCSE is a satellite limited care center (providing only hemodialysis outside a hospital setting)
with its own management autonomy, which generally cares for patients with a lower comorbidity index.
The study was approved by the IIS-Fundación Jiménez Díaz Ethics Committee (PIOH036-20_FJD)
and was performed in accordance with the Declaration of Helsinki and the European Union Clinical
Trial Directive. Patients were enrolled after providing written informed consent.
In March 2020, UHFJD had 58 patients in a chronic hemodialysis program and FRCSE had 142
additional patients (200 patients in total, aged over 18 years) (Figure 1). Both centers cooperate to care
for chronic hemodialysis patients: stable patients are transferred from UHFJD to FRCSE and, if they
become unstable, they are bought back to the hospital-based UHFJD. The study was conducted on patients
suspected of having an infection, i.e., who presented clinical symptoms compatible with COVID-19 or
asymptomatic patients in close contact with individuals with suspected or confirmed active infection.
Patients were screened for symptoms daily. Patients from FRCSE with a diagnosis of COVID-19 were
transferred to UHFJD and this study was performed among UHFJD patients, which include some
transferred from FRCSE, as detailed below.
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Figure 1. Hemodialisis patients diagnostic flow chart. HD: hemodialysis; PCR +: PCR positive 
patients; PCR −: PCR negative patients; Ab +: SARS-CoV-2 seropositive patients; Ab −: No antibodies. 
2.1. COVID-19 Diagnosis 
Between March and April 2020, the FJD unit had a total of 66 patients, who were all tested for 
SARS-CoV-2 by PCR. Of these, 27 patients were transferred from FRCSE to UHFJD, as they needed 
hospital admission (17/27) and/or were positive for COVID-19 as outpatients (10/27). The remaining 
39 patients from HUFJD included patients with symptoms (34/39) compatible with COVID-19 or 
close contact with symptomatic individuals, as well as 5/39 UHFJD patients who were tested, because 
they had shared the dialysis unit with COVID-19 patients. 
The PCR test for SARS-CoV-2 consists of a nucleic acid extraction from nasopharyngeal swab 
samples and subsequent amplification by real-time RT-PCR using ORF1ab and N genes as targets. 
Serological (IgM/IgG) tests were also performed using ELISA (VIRCELL, Granada, Spain). 
Sensitivity: IgG: 100% (19 days after PCR positive), IgM: 82–88% (7 days after PCR positive) 
/specificity IgG: 98%, IgM: 98.8%. 
2.2. Additional Tests 
A COVID-19-related analytical panel included hemogram, lymphocyte profile, ferritin and 
interleukin-6 (IL-6) as markers of inflammation, D-dimer as a marker of vascular damage, and 
Troponin I as a marker of myocardial damage. Those with high suspicion of COVID-19 were 
subjected to a chest X-ray. 
2.3. Prevention and Treatment 
Droplet respiratory protection measures with a surgical mask for both patients and staff, hand 
washing and other isolation measures were initiated on February 24, 2020, two weeks before the first 
COVID-19 patient was diagnosed. 
Admission criteria were based on the presence of pneumonia, oxygen saturation below 94% (or 
hypoxemia evidenced in arterial blood) and/or significant deterioration in general condition. Initial 
treatment for all admitted patients and outpatients was according to the weekly updated protocol of 
Figure 1. Hemodialisis patients diagnostic flow chart. HD: hemodialysis; PCR +: PCR positive patients;
PCR −: PCR negative patients; Ab +: SARS-CoV-2 seropositive patients; Ab −: No antibodies.
2.1. COVID-19 Diagnosis
Between March and April 2020, the FJD unit had a total of 66 patients, who were all tested for
SARS-CoV-2 by PCR. Of these, 27 patients were transferred from FRCSE to UHFJD, as they needed
hospital admission (17/27) and/or were positive for COVID-19 as outpatients (10/27). The remaining
39 patients from HUFJD included patients with symptoms (34/39) compatible with COVID-19 or close
contact with symptomatic individuals, as well as 5/39 UHFJD patients who were tested, because they
had shared the dialysis unit with COVID-19 patients.
The PCR test for SARS-CoV-2 consists of a nucleic acid extraction from nasopharyngeal swab
samples and subsequent amplification by real-time RT-PCR using ORF1ab and N genes as targets.
Serological (IgM/IgG) tests were also performed using ELISA (VIRCELL, Granada, Spain). Sensitivity:
IgG: 100% (19 days after PCR positive), IgM: 82–88% (7 days after PCR positive)/specificity IgG: 98%,
IgM: 98.8%.
2.2. Additional Tests
A COVID-19-related analytical panel included hemogram, lymphocyte profile, ferritin
and interleukin-6 (IL-6) as markers of inflammation, D-dimer as a marker of vascular damage, and Troponin
I as a marker of myocardial damage. Those with high suspicion of COVID-19 were subjected to a chest X-ray.
2.3. Prevention and Treatment
Droplet respiratory protection measures with a surgical mask for both patients and staff,
hand washing and other isolation measures were initiated on February 24, 2020, two weeks before the
first COVID-19 patient was diagnosed.
Admission criteria were based on the presence of pneumonia, oxygen saturation below 94% (or
hypoxemia evidenced in arterial blood) and/or significant deterioration in general condition. Initial
treatment for all admitted patients and outpatients was according to the weekly updated protocol
of the FJD. Treatment consisted of hydroxychloroquine (200 mg/12 h for 5 days) and antibiotics
(doxycycline 100 mg/12 h for 5 days or levofloxacin 250 mg/48 h for 5 days). In case of acute respiratory
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insufficiency and inflammatory signs, such as marked elevation of ferritin and C-reactive protein,
glucocorticoids were added (250 mg/day Methylprednisolone for 3 days, followed by oral prednisone
40 mg every 12 h for 3–4 days). Prophylactic tinzaparin (3500 IU/day) was prescribed for those with
analytical data of procoagulant status, i.e., D-dimer elevation or with markers of acute myocardial
damage. For bilateral pneumonia and/or oxygen saturation below 94%, Lopinavir-Ritonavir (Kaletra
400 mg/12 h for 5 days) was added and finally, in the most severe cases, Tocilizumab 400 mg (maximum
2 doses in 48 h) was added, if the oxygen requirement was between 10–15 L/min. Oxygen therapy was
initiated when oxygen fell below 93%. The most severe cases were admitted to the ICU. Hemodialysis
was performed in an independent isolation room for PCR-positive cases.
2.4. Statistical Data Analysis
Quantitative variables were described using the mean and standard deviation or the median
and interquartile range. Qualitative variables were described by means of absolute and relative
frequencies. Groups were compared with the Student t-test or the Mann-Whitney test, depending on
the normality of the data (Shapiro-Wilk test) for quantitative variables, and the Chi-square test for
qualitative variables, using R version 4.0 (R Foundation for Statistical Computing) [18].
3. Results
3.1. COVID-19 Diagnosis
Of 200 patients on hemodialysis distributed between two associated centers, 66 patients were
tested for SARS-CoV-2 by PCR between March and April 2020. In addition, anti-SARS-CoV-2 antibodies
were studied in 57/66 (86.4%) patients.
In total, 48/200 (24%) patients were diagnosed as COVID-19: 38/48 (79%) based on positive PCR;
eight out of 48 (17%) patients with negative PCR were diagnosed based on seroconversion and two (4%)
had a clinical diagnosis (Figure 1). The clinical diagnosis despite negative PCR and anti-SARS-CoV-2
antibodies was based on clinical features: they required admission for typical COVID-19 clinical,
radiological (unilateral or bilateral pneumonia) and analytical features (very low lymphocyte counts,
higher D-dimer values than other hemodialysis non-affected patients and high IL-6 levels) (Table S1).
The mean age of COVID-19 patients was 72.6 years, and 16 (33%) were females (Table 1).
Anti-SARS-CoV-2 antibodies were studied in 29/38 (88%) of PCR-positive patients and in all
PCR-negative patients. Among PCR positive patients, 17 (45%) were IgM positive and 17 were IgG
positive. Five (13%) PCR positive patients remained with negative serology, a mean of 13.2 ± 5.2 days
after PCR positivity. Among PCR-patients, eight out of 28 (28.6%) became positive for IgM and four
(11%) were additionally positive for IgG.
3.2. Clinical Features of Patients with Positive and Negative PCR
The overall incidence of PCR positive COVID-19 was similar in both centers: 27/142 (19%) in
FRCSE, and 11/58 (19%) in UHFJD. FRCSE PCR positive patients were moved to UHFJD. A majority
(68.4%) were men and the mean age was 73.4 ± 11.9 years (Table 1, Table S2). Of PCR positive patients,
21/38 (55.3%) required hospital admission and five out of 38 died (13%). One patient was admitted to
the intensive care unit (ICU). Disease was less severe in PCR negative patients, who had a lower need
for admission (three admissions: 30%, p = 0.42 and no deaths were recorded. Moreover, COVID-19 was
more symptomatic in PCR positive patients: 87% had symptoms, as opposed to 40% of PCR negative
patients (p = 0.001) (Table S2). The most frequent symptom in both groups of patients was fever found
in 36% of PCR positive and 30% of PCR negative patients). Additional presenting symptoms were
general malaise, cough, diarrhea, dyspnea, arrhythmia, chest pain and nausea.
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Table 1. Characteristics of patients with positive and negative polymerase chain reaction (PCR).
Data presented as mean ± SD, median (interquartile range) or counts (percentage).
Characteristics
Positive PCR Negative PCR
p-Value
(N = 38) (N = 10)
Age, years 73.4 ±11.86 69.5 ±15.3 ns
Time in dialysis, days 1101 (191–1624) 1010 (415–1157)
Female, n (%) 12 (31.6) 4 (40) ns
Hospital admission, n (%) 21 (55.3) 3 (30) 0.042
Symptoms, n (%) 33 (86.8) 4 (40) 0.001
Asymptomatic 5 (13.2) 6 (60)
Oxygen saturation; % 94 (20) 96 (10) ns
Chest X-ray, n (%) ns
Normal 12 (31.5) 1 (10)
Unilateral pneumonia 8 (21.1) 1 (10)
Bilateral pneumonia 18 (44.7) 1 (10)
No 7
Laboratory analysis
Hemoglobin, g/dL 11.28 ±1.45 11.40 ±1.56 ns
Lymphocytes, /µL n 700 (500–1000) 950 (825–1225) ns
D dimer n, µg/L n 1127 (710–1772) 1308 (692–1774) ns
Ferritin, ng/mL 923 (393–1422) 340 (222–807) 0.062
Troponin I n, ng/mL n 0.050 (0.020–0.098) 0.012 (0.001–0.040) 0.033
IL-6 n, pg/mL n 15.40 (7.03–54.25) 15.66 (3.47–21.23) ns
Serology, n (%) 29 (76.3) 27 (96.4)
IgM, n (%)
Positive 17 (58.6) 8 (25.9) 0.012
Undetermined 4 (13.8) 0 (7.4)
Negative 8 (27.6) 2 (66.7)
IgG, n (%)
Positive 17 (58.6) 4 (40) < .001
Undetermined 4 (13.8) 0 (0)
Negative 8 (27.6) 6 (60)
IgG + IgM positive, n (%) 15 (51.7) 4 (40) < .001
Deaths, n (%) 5 (13.2) 0
n Normal range: Lymphocytes 1200–5000/ µL; D-dimer 68–494 µg/L, Troponin I < 0.08 ng/mL, IL6 < 7 pg/mL.
PCR: polymerase chain reaction; IL-6: interleukin-6; IgM: immunoglobulin M; IgG: immunoglobulin G; ns:
non-significant variables.
PCR positive and negative patients did not display differences in oxygen saturation or in several
analytical parameters associated with COVID-19, including low lymphocyte counts, high D-dimer
levels or high IL-6 levels. Low lymphocyte counts in patients diagnosed with COVID-19 were not
present months earlier. However, serum troponin I levels were higher in PCR positive patients:
0.050 (0.020–0.098) vs. 0.012 (0.001–0.040); p = 0.033 (Table 1). Among patients who had chest X-ray,
normal chest X-ray, unilateral and bilateral pneumonia was observed in both patients with positive
and negative PCR.
3.3. Need for Hospitalization
The characteristics of hospitalized and non-hospitalized PCR positive patients are shown in Table 2
and Table S3 and for PCR negative patients in Table 3 and Table S4. Among PCR positive patients,
there was a non-significant numerical towards higher X-ray severity and lower oxygen saturation.
However, only lymphocyte counts were significantly lower in hospitalized patients: non-hospitalized
950 (600–1250) vs hospitalized 600 (300–700), p = 0.007. This was also the case for PCR negative
patients—non-hospitalized: 1000 (900–1350) vs hospitalized: 400 (300–700); p = 0.04. A non-significant
numerical towards higher serum IL-6 levels was also observed for both hospitalized PCR positive
and hospitalized PCR negative patients.
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Table 2. Analysis of polymerase chain reaction (PCR) positive patients, according to hospitalization related
to disease severity. Data presented as mean ± SD, median (interquartile range) or counts (percentage).
Characteristics
Hospitalization
p-Value
No (N = 17) Yes (N = 21)
Age, years 72.9 ±13.6 73.7 ±10.8 ns
Dialysis vintage, days 1011 (1501571) 1360 (251–1614)
Female, n (%) 4 (25) 8 (36) ns
Symptoms, n (%) 12 (68.75) 21 (100) ns
Asymptomatic 5 (31.25) 0
Oxygen saturation, % 94.13 ±4.78 91.86 ±4.84 ns
Chest X-ray, n (%) 0.067
Normal 8 (50) 4 (18.2)
Unilateral pneumonia 4 (25) 4 (18.2)
Bilateral pneumonia 4 (18.75) 14 (63.6)
Laboratory analysis
Hemoglobin, g/dL 11.7 ±1.2 11.1 ±1.6 0.089
Lymphocytes, /µL n 950 (600–1250) 600 (300–700) 0.007
D dimer n,, µg/L 1045 (499–1379) 1475 (798–2240) 0.17
Ferritin, ng/mL 733 (365–1457) 956 (654–1412) ns
Troponin I n, ng/mL 0.050 (0.012–0.065) 0.050 (0.025–0.215) ns
IL-6 n, pg/mL 9.49 (5.74–17.35) 32.20 (11.07–64.92) ns
Serology, n (%) 14 (87.5) 15 (68.2)
IgM, n (%) ns
Positive 11 (78.6) 8 (53.3)
Negative 3 (21.4) 7 (46.7)
IgG, n (%) 0.062
Positive 12 (85.7) 7 (46.7)
Negative 2 (14.3) 8 (53.3)
IgG + IgM positive, n (%) 11 (78.6) 6 (40)
Deaths, n (%) 0 5 (22.7)
n Normal range: Lymphocytes 1200–5000/ µL; D-dimer 68–494 µg/L, Troponin I < 0.08 ng/mL, IL-6 < 7 pg/mL. IL-6:
interleukin-6; IgM: immunoglobulin M; IgG: immunoglobulin G; ns: non-significant variables.
3.4. Outcomes
At the end of follow-up, 18/38 (47%) patients with positive PCR have become negative, are
asymptomatic for fever, cough and/or dyspnea and are integrated in the general dialysis room;
11/38 (28.9%) are clinically stable, although they persist with positive PCR and are being dialyzed in
the COVID-19 isolation unit and four out of 48 (10.5%) were still hospitalized (three in a general ward
and one in the ICU).
Overall mortality between March and April 2020 was five out of 48 (10.4%) patients, but it was 30%
higher in PCR positive patients: five out of 38 (13.2%), while no PCR negative patient died. The mean
age of the deceased was 79 ± 4 years. Interestingly, the highest mortality (two out of six; 33.3%) was
found among patients on hemodialysis for less than 3 months. Both patients were immunosuppressed
for underlying diseases (myeloma and vasculitis, respectively). By contrast, the mortality among
chronic (>3 months) hemodialysis patients was three out of 42 (7.1%). These other three positive PCR
patients died from acute myocardial infarction (one) and from respiratory failure (two).
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Table 3. Analysis of polymerase chain reaction (PCR) negative patients according to hospitalization
related to disease severity. Data presented as mean ± SD, median (interquartile range) or counts
(percentage).
Characteristics
Hospitalization
p-Value
No (N = 7) Yes (N = 3)
Age, years 66.8 ±16.75 76 ±10.50
Time in dialysis, days 1118 (268–3035) 757 (111–1766) ns
Female, n (%) 3 (42.9) 1 (33.3) ns
Symptoms, n (%) 1 (14.3) 3 (100)
Asymptomatic 6 (85.7) 0
Oxygen saturation, % no data 94 ±3
Chest X-ray, n (%)
Normal 1 (14.3) 0
Unilateral pneumonia 0 1 (33.3)
Bilateral pneumonia 0 2 (66.7)
No 6 (85.7) 0
Clinical analysis
Hemoglobin, g/dL 11.1 ±1.53 12.0 ±1.75
Lymphocytes n, /µL 1000 (900–1350) 400 (300–700) 0.04
D dimer n, µg/L 1512 (577–1754) 1105 (938–1528) ns
Ferritin, ng/mL 346 (229–730) 335 (217–1432) ns
Troponin I n, ng/mL 0.026 (0.004–0.040) 0.010 (0.006–0.045) ns
IL-6 n, pg/mL 3.8 (3.2–15.7) 41.7 (31.2–144.8) ns
Serology, n (%) 7 (100) 3 (100)
IgM, n (%) ns
Positive 7 (100) 1 (33.3)
Undetermined 0 0
Negative 0 2 (66.7)
IgG, n (%) ns
Positive 3 (42.9) 1 (33.3)
Undetermined 0 0
Negative 4 (57.1) 2 (66.7)
IgG + IgM positive, n (%) 3 (42.9) 0
Deaths, n (%) 0 0
n Normal range: Lymphocytes 1200–5000/ µL; D-dimer 68–494 µg/L, Troponin I < 0.08 ng/mL, IL-6 < 7 pg/mL. IL-6:
interleukin-6; IgM: immunoglobulin M; IgG: immunoglobulin G; ns: non-significant variables.
4. Discussion
The main findings of this study are that, among hemodialysis patients, there is a high incidence
of oligosymptomatic patients, as well as of infected patients with negative PCR results. The disease
spectrum is further expanded by patients who are undistinguishable from a clinical, radiological
and analytical point of view from bona fide COVID-19 patients, yet are PCR and anti-SARS-CoV-2
antibody negative. In this regard, seroconversion was not observed in all hemodialysis COVID-19
patients. A strategy of early diagnosis and treatment was associated with mortality in the range
described for the general population of similar age [18], and lower than for some European hemodialysis
series, and in the range found in some Chinese centers caring for younger hemodialysis patients
(Table S5) [17,19–22].
In the FJD unit, we had a policy of early PCR in patients with suggestive symptoms or having
cohabitated with infected individuals. In one month, most patients had been tested, and in two months,
the whole unit was tested. The asymptomatic positive patients had had contact with symptomatic
family members. Current recommendations in closed populations are to test all residents [16], but how
frequent testing is needed is not easily determined.
The suspicion of COVID-19 in hemodialysis patients is not easy. Disease can be oligosymptomatic
and PCR repeatedly negative, despite clinical and analytical features very suggestive of COVID-19,
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and the diagnosis confirmed by antibody detection. Waiting for the seroconversion of PCR- patients
may unnecessarily delay the therapy and dynamics of seroconversion in hemodialysis patients is poorly
characterized. In this regard, our study provides further data by analyzing IgG and IgM seroconversion
in hemodialysis patients. No study has so far analyzed this response in hemodialysis patients. In the
general population anti-SARS-CoV antibodies first appear from day 3–42 for IgM and from day 5–47 for
IgG antibodies [23], while anti-SARS-CoV-2 antibodies develop from day 9–10 after first symptoms [24].
However, in the prior SARS-CoV epidemic, the mean time for seroconversion was 20 days, at which
time only 60–75% of patients had IgG against the virus [25]. In patients with confirmed SARS-CoV-2
infection in China, the mean time for seroconversion was 11–14 days, depending on the immunological
assay used and 94.3% (IgM) and 79.8% (IgG) of patients seroconverted after 15 days [26]. In our case,
13% of PCR positive patients had not yet seroconverted at the last follow-up, a mean of 13 days after
PCR positivity. As with other infections and vaccines, hemodialysis patients may have a reduced
immunogenic response [5].
The most common symptoms of COVID-19 were fever (44% on admission and 89% during
hospitalization), fatigue, shortness of breath and dry cough (68%), although many patients also had
gastrointestinal symptoms, such as nausea and diarrhea [27]. In our series, PCR positive hemodialysis
patients presented fever (31.5%), cough (10.5%) and diarrhea (10.5%) as the most frequent symptoms.
Thus, they may be less symptomatic than the general population, although our policy of early
testing may have identified milder cases that may have not been diagnosed in a general population
setting. In the literature, lymphopenia was present in 83% of COVID-19 patients on admission [28].
Lymphopenia was also a defining characteristic in COVID-19 hemodialysis patients.
Pneumonia is the most frequent complication of COVID-19 [29]. In our series, 56% of hemodialysis
patients developed pneumonia as detected by X-ray, the majority of which were bilateral. This is in
line with general population Chinese data, in which no X-ray abnormalities were found in 40% of the
patients. This is reason why, in China, all patients underwent a chest CT scan, finding pathological
abnormalities in 86% of the cases. Three of our hemodialysis patients died of respiratory failure.
While a more limited series of five hemodialysis patients with pneumonia described good outcomes,
with none of them dying despite all presenting fever, cough and lymphopenia [30], this Chinese
report is in line with the findings in our study of a large variability in clinical presentation among
hemodialysis patients.
Spontaneous lymphopenia can be found in patients on hemodialysis [31], so it may present
interpretation problems for suspected COVID-19. In our series, the mean lymphocyte counts in PCR
positive patients in the three months prior to infection was 1300 ± 595 per µL, while median values
at diagnosis was 700 per µL. This is in line with prior descriptions of a total lymphocyte decrease in
COVID-19, especially if pneumonia develops [32]. Frequently, analytical monitoring in hemodialysis
patients means that, contrary to the general population, an acute drop in lymphocytes as compared to
the prior control value can be observed. Ferritin was also elevated in PCR positive patients, but did
not increase with the severity of the condition. D-dimer also increases in severe COVID-19 patients,
indicating vascular damage. However, D-dimer is a marker that is elevated in dialysis patients [13,33].
In populations with preserved renal function, the most frequent cause of death was severe
respiratory failure, which causes lung and systemic inflammation, leading to multiorgan failure in
patients with comorbidities. Other frequent causes of death were sepsis and heart failure [22,27].
In our study, the mortality pattern presented several aspects that merit discussion, and should be
validated in multicenter studies. First, mortality was concentrated in the oldest patients, and in
unstable patients who had just started hemodialysis for diseases in which the immune system was
additionally compromised by the causative disease itself and/or its treatment. In this regard, it is well
known that the mortality rate in patients entering dialysis, especially elderly patients, is higher in the
first 90 days of initiating dialysis [34,35]. While it has been discussed to what extent SARS-CoV-2 could
be a by-stander in some patients with severe comorbidities, it is also true that these patients are at
higher risk of severe COVID-19, and that the worldwide consensus so far has been to attribute the
J. Clin. Med. 2020, 9, 2264 9 of 12
death to COVID-19 if the patient was infected by SARS-CoV-2. Second, mortality was concentrated
among PCR positive patients. This would be aligned with the idea that these patients may have higher
viral loads. In this regard, the active search of a COVID-19 diagnosis resulted in the identification of
individuals with milder disease and, potentially, to an earlier prescription of therapy. This may explain
the mortality rate that appeared to be lower than in European centers caring for patients of similar age,
and in the range described for Chinese centers caring for patients that were around a decade younger,
and in which all hemodialysis patients were screened for COVID-9 (Table S5).
In COVID-19, there are two distinct but overlapping pathophysiological mechanisms, the first
triggered by the virus itself, and the second by the host response. At the time of the cases reported,
treatment remained empirical. Drug therapy directed against the virus shows the greatest promise when
applied early in the course of the disease, but its usefulness in advanced stages may be questionable [36].
Anti-inflammatory therapy introduced too early may not be necessary, and could even encourage
viral replication, as in the case of corticosteroids [37]. In our series, anti-inflammatory therapy was
prescribed when there were signs of clinical or analytical severity. Recommended anti-inflammatory
therapy includes corticosteroids, IL-6 antagonists (tocilizumab) and JAK inhibitors (Baricitinib) [38].
Several limitations should be acknowledged. Given the small sample size and quasi-single center
(two interconnected hemodialysis units) nature of the study, these data may not be generalizable.
Additionally, some patients were diagnosed based on serological tests, which have been criticized
and two were diagnosed on clinical grounds. The latter is also one of the strengths of the study,
since the knowledge that some patients with typical clinical and analytical features can be PCR
negative, and may not be tested for antibodies or these may be negative, has strong consequences for
preventive and isolation strategies. Indeed, hemodialysis patients are known to mount suboptimal
antibody responses to a variety of antigenic challenges. Additionally, there is increasing evidence
that, even in the general population, anti-SARS-CoV-2 antibodies may be negative both in the acute
and the convalescent phase of the disease, and some patients without detectable antibodies have
evidence of infection, as detected by either PCR or specific T-cell reactive cells [39,40]. In this regard,
the only two patients to have been diagnosed as having COVID-19, despite negative PCR and serology,
had typical COVID-19 features, including severe lymphopenia coincident with symptoms, pneumonia
and increased D-Dimer and IL-6 levels. Given the advancing understanding of the disease, it is possible
that some patients not considered to have had COVID-19 based on PCR and serology may indeed
have had the disease. Finally, as patients did not have a long-term follow-up, the impact of COVID-19
on morbidity and mortality may have been underestimated.
5. Conclusions
In conclusion, given uremic immunosuppression and the high prevalence of comorbidities,
hemodialysis patients may be particularly vulnerable to COVID-19. The diagnosis is complicated by
the presence of PCR-negative patients, and the high incidence of oligosymptomatic individuals. Efforts
to identify and treat patients early may limit the spread of the virus and improve outcomes. We suggest
that PCR should be performed on hemodialysis patients, including those with mild symptoms,
and asymptomatic patients with possible exposure to COVID-19 or affected relatives. The use of this
approach resulted in an overall mortality in the range observed for the general population of the
same age.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/7/2264/s1,
Table S1: Characteristics of PCR negative patients according to diagnosis of COVID-19. Only symptoms presented
by at least 1 patient are represented. Data presented as mean ± SD, median (interquartile range) or counts
(percentage), Table S2. Characteristics of patients with positive and negative PCR. Data presented as mean
± SD, median (interquartile range) or counts (percentage), Table S3. Analysis of PCR positive patients according
to hospitalization related to disease severity. Data presented as mean ± SD, median (interquartile range) or
counts (percentage), Table S4. Analysis of PCR negative patients according to hospitalization related to disease
severity. Data presented as mean ± SD, median (interquartile range) or counts (percentage), Table S5. COVID-19
hemodialysis cohorts.
J. Clin. Med. 2020, 9, 2264 10 of 12
Author Contributions: Conceptualization, E.G.-P.; Data curation, T.S.d.C., E.G.-G., A.A. and S.M.-F.; Formal
analysis, S.M.-F.; Investigation, T.S.d.C., E.G.-G. and A.A.; Resources, M.P.-G.; Supervision, E.G.-P.; Validation,
A.O.; Writing—original draft, T.S.d.C. and E.G.-P.; Writing—review & editing, A.O. All authors have read
and agreed to the published version of the manuscript.
Funding: The Renal: Vascular and Diabetes Laboratory is funded by Ministerio de Economia, Industria y
competitividad: Research support from FIS ISCIII FEDER funds PI16/01298, PI15/00298, PI16/02057, PI16/01900,
PI19/00815, DTS18/00032 ISCIII-RETIC REDinREN RD16/0009, CYTED IBERERC and Sociedad Madrileña de
Nefrologia, ERA-PerMed-JTC2018 (KIDNEY ATTACK AC18/00064 and PERSTIGAN AC18/00071), Comunidad
de Madrid CIFRA2 B2017/BMD-3686. to AO.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. De Jager, D.J.; Grootendorst, D.C.; Jager, K.J.; Van Dijk, P.C.; Tomas, L.M.J.; Ansell, D.; Collart, F.; Finne, P.;
Heaf, J.G.; De Meester, J.; et al. Cardiovascular and noncardiovascular mortality among patients starting
dialysis. JAMA-J. Am. Med. Assoc. 2009, 302, 1782–1789. [CrossRef] [PubMed]
2. Ortiz, A.; Covic, A.; Fliser, D.; Fouque, D.; Goldsmith, D.; Kanbay, M.; Mallamaci, F.; Massy, Z.A.; Rossignol, P.;
Vanholder, R.; et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney
failure. Lancet 2014, 383, 1831–1843. [CrossRef]
3. Sarnak, M.J.; Jaber, B.L. Pulmonary infectious mortality among patients with end-stage renal disease. Chest
2001, 120, 1883–1887. [CrossRef] [PubMed]
4. Sarnak, M.J.; Jaber, B.L. Mortality caused by sepsis in patients with end-stage renal disease compared with
the general population. Kidney Int. 2000, 58, 1758–1764. [CrossRef]
5. Kato, S.; Chmielewski, M.; Honda, H.; Pecoits-Filho, R.; Matsuo, S.; Yuzawa, Y.; Tranaeus, A.; Stenvinkel, P.;
Lindholm, B. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 2008, 3,
1526–1533. [CrossRef]
6. Stenvinkel, P.; Ketteler, M.; Johnson, R.J.; Lindholm, B.; Pecoits-Filho, R.; Riella, M.; Heimbürger, O.;
Cederholm, T.; Girndt, M. IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia
-The good, the bad, and the ugly. Kidney Int. 2005, 67, 1216–1233. [CrossRef]
7. Elewa, U.; Sanchez-Niño, M.D.; Martin-Cleary, C.; Fernandez-Fernandez, B.; Egido, J.; Ortiz, A.
Cardiovascular risk biomarkers in CKD: The inflammation link and the road less traveled. Int. Urol. Nephrol.
2012, 44, 1731–1744. [CrossRef]
8. Smeeth, L.; Thomas, S.L.; Hall, A.J.; Hubbard, R.; Farrington, P.; Vallance, P. Risk of myocardial infarction
and stroke after acute infection or vaccination. N. Engl. J. Med. 2004, 351, 2611–2618. [CrossRef]
9. Macdougall, I.C.; Bhandari, S.; White, C.; Anker, S.D.; Farrington, K.; Kalra, P.A.; Mark, P.B.; McMurray, J.J.V.;
Reid, C.; Robertson, M.; et al. Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis:
A Prespecified Secondary Analysis of the PIVOTAL Trial. J. Am. Soc. Nephrol. 2020, 31, 1118–1127,
ASN.2019090972. [CrossRef]
10. World Health Organization WHO/Europe Recommendations on Influenza Vaccination during the 2012–2013
Winter Season. Available online: https://www.euro.who.int/__data/assets/pdf_file/0006/175254/WHO-
Europe-recommendations-on-influenza-vaccination-during-the-2012-2013-winter-season.pdf (accessed
on 4 May 2020).
11. Chang, Y.T.; Guo, C.Y.; Tsai, M.S.; Cheng, Y.-Y.; Lin, M.-T.; Chen, C.H.; Shen, D.; Wang, J.R.; Sung, J.M.
Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1
influenza virus A in the adult and elder hemodialysis patients. Vaccine 2012, 30, 5009–5018. [CrossRef]
12. Mastalerz-Migas, A.; Gwiazda, E.; Brydak, L.B. Effectiveness of influenza vaccine in patients on
hemodialysis-A review. Med. Sci. Monit. 2013, 19, 1013–1018. [PubMed]
13. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course
and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort
study. Lancet 2020, 395, 1054–1062. [CrossRef]
J. Clin. Med. 2020, 9, 2264 11 of 12
14. Wölfel, R.; Corman, V.M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M.A.; Niemeyer, D.; Jones, T.C.;
Vollmar, P.; Rothe, C.; et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020,
581, 465–469. [CrossRef] [PubMed]
15. Ip, D.K.M.; Lau, L.L.H.; Leung, N.H.L.; Fang, V.J.; Chan, K.-H.; Chu, D.K.W.; Leung, G.M.; Peiris, J.S.M.;
Uyeki, T.M.; Cowling, B.J. Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic
Influenza Virus Infections in the Community. Clin. Infect. Dis. 2017, 64, 736–742. [PubMed]
16. Arons, M.M.; Hatfield, K.M.; Reddy, S.C.; Kimball, A.; James, A.; Jacobs, J.R.; Taylor, J.; Spicer, K.;
Bardossy, A.C.; Oakley, L.P.; et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled
Nursing Facility. N. Engl. J. Med. 2020, 382, 2081–2090. [CrossRef]
17. Ma, Y.; Diao, B.; Lv, X.; Zhu, J.; Liang, W.; Liu, L.; Bu, W.; Cheng, H.; Zhang, S.; Yang, L.; et al. 2019 Novel
Coronavirus Disease in Hemodialysis (HD) Patients: Report from One HD Center in Wuhan, China. Available
online: https://europepmc.org/article/ppr/ppr114695 (accessed on 24 May 2020).
18. Wu, J.; Li, W.; Shi, X.; Chen, Z.; Jiang, B.; Liu, J.; Wang, D.; Liu, C.; Meng, Y.; Cui, L.; et al. Early antiviral
treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus
disease (COVID-19). J. Intern. Med. 2020, 288, 128–138. [CrossRef]
19. Albalate, M.; Arribas, P.; Torres, E.; Cintra, M.; Alcázar, R.; Puerta, M.; Ortega, M.; Procaccini, F.; Martin, J.;
Jiménez, E.; et al. Alta prevalencia de covid19 asintomático en hemodiálisis. Aprendiendo dia a dia el primer
mes de pandemia de covid19. Nefrología 2020, 40, 279–286. [CrossRef]
20. Alberici, F.; Delbarba, E.; Manenti, C.; Econimo, L.; Valerio, F.; Pola, A.; Maffei, C.; Possenti, S.; Piva, S.;
Latronico, N. Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2
(COVID-19) Pandemic in Brescia, Italy. Kidney Int. Rep. 2020, 5, 580–585. [CrossRef]
21. Scarpioni, R.; Manini, A.; Valsania, T.; Amicis, S.D.; Albertazzi, V.; Melfa, L.; Ricardi, M.; Rocca, C. Covid-19
and its impact on nephropathic patients: The experience at Ospedale “Guglielmo da Saliceto” in Piacenza.
G. Ital. Nefrol. 2020, 37, 2.
22. Chen, T.; Wu, D.; Chen, H.; Yan, W.; Yang, D.; Chen, G.; Ma, K.; Xu, D.; Yu, H.; Wang, H.; et al. Clinical
characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ 2020, 368,
1158–1163. [CrossRef]
23. Chen, X.; Zhou, B.; Li, M.; Liang, X.; Wang, H.; Yang, G.; Wang, H.; Le, X. Serology of Severe Acute Respiratory
Syndrome: Implications for Surveillance and Outcome. J. Infect. Dis. 2004, 189, 1158–1163. [CrossRef]
[PubMed]
24. Haveri, A.; Smura, T.; Kuivanen, S.; Österlund, P.; Hepojoki, J.; Ikonen, N.; Pitkäpaasi, M.; Blomqvist, S.;
Rönkkö, E.; Kantele, A.; et al. Serological and molecular findings during SARS-CoV-2 infection: The first
case study in Finland, January to February 2020. Eurosurveillance 2020, 25, 1767–1772. [CrossRef] [PubMed]
25. Peiris, J.S.M.; Chu, C.M.; Cheng, V.C.C.; Chan, K.S.; Hung, I.F.N.; Poon, L.L.M.; Law, K.I.; Tang, B.S.F.;
Hon, T.Y.W.; Chan, C.S.; et al. Clinical progression and viral load in a community outbreak of
coronavirus-associated SARS pneumonia: A prospective study. Lancet 2003, 361, 1767–1772. [CrossRef]
26. Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; et al. Antibody responses
to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. 2020, 323, 1061–1069.
27. Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; et al. Clinical
Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
China. JAMA-J. Am. Med. Assoc. 2020, 323, 1061–1069. [CrossRef] [PubMed]
28. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al.
Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720.
[CrossRef]
29. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological
and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive
study. Lancet 2020, 395, 507–513. [CrossRef]
30. Wang, R.; Liao, C.; He, H.; Hu, C.; Wei, Z.; Hong, Z.; Zhang, C.; Liao, M.; Shui, H. COVID-19 in Hemodialysis
Patients: A Report of 5 Cases. Am. J. Kidney Dis. 2020, 76, 141–143. [CrossRef]
31. Fernández-Fresnedo, G.; Ramos, M.A.; González-Pardo, M.C.; de Francisco, A.L.; López-Hoyos, M.;
Arias, M. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2.
Nephrol. Dial. Transplant. 2000, 15, 502–510. [CrossRef]
J. Clin. Med. 2020, 9, 2264 12 of 12
32. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features
of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395, 497–506. [CrossRef]
33. Gubensek, J.; Lolic, M.; Ponikvar, R.; Buturovic-Ponikvar, J. D-dimer levels in maintenance hemodialysis
patients: High prevalence of positive values also in the group without predisposing diseases. Hemodial. Int.
2016, 20, 198–203. [CrossRef] [PubMed]
34. Kramer, A.; Pippias, M.; Noordzij, M.; Stel, V.S.; Afentakis, N.; Ambühl, P.M.; Andrusev, A.M.; Fuster, A.M.;
Monzón, F.E.A.; Åsberg, A.; et al. The European Renal Association-European Dialysis and Transplant
Association (ERA-EDTA) Registry Annual Report 2015: A Summary. Clin. Kidney J. 2018, 11, 108–122.
[CrossRef] [PubMed]
35. Kramer, A.; Pippias, M.; Noordzij, M.; Stel, V.S.; Andrusev, A.M.; Aparicio-Madre, M.I.; Monzón, F.E.A.;
Åsberg, A.; Barbullushi, M.; Beltrán, P. The European Renal Association-European Dialysis and Transplant
Association (ERA-EDTA) Registry Annual Report 2016: A Summary. Clin. Kidney J. 2019, 12, 702–720.
[CrossRef] [PubMed]
36. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir
and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.
2020, 30, 269–271. [CrossRef]
37. Russell, C.D.; Millar, J.E.; Baillie, J.K. Clinical evidence does not support corticosteroid treatment for
2019-nCoV lung injury. Lancet 2020, 395, 473–475. [CrossRef]
38. Zhang, W.; Zhao, Y.; Zhang, F.; Wang, Q.; Li, T.; Liu, Z.; Wang, J.; Qin, Y.; Zhang, X.; Yan, X.; et al. The use
of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19):
The experience of clinical immunologists from China. Clin. Immunol. 2020, 214, 108–393. [CrossRef]
39. Long, Q.-X.; Tang, X.-J.; Shi, Q.-L.; Li, Q.; Deng, H.-J.; Yuan, J.; Hu, J.-L.; Xu, W.; Zhang, Y.; Lv, F.-J.; et al.
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020, 1–12.
[CrossRef]
40. Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.-B.; Olsson, A.; Llewellyn-Lacey, S.;
Kamal, H.; Bogdanovic, G.; Muschiol, S.; et al. Robust T cell Immunity in Convalescent Individuals with
Asymptomatic or Mild COVID-19. Available online: https://www.biorxiv.org/content/10.1101/2020.06.29.
174888v1 (accessed on 3 July 2020).
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
